Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial
出版年份 2022 全文链接
标题
Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CANCER
Volume 174, Issue -, Pages 40-47
出版商
Elsevier BV
发表日期
2022-08-13
DOI
10.1016/j.ejca.2022.06.010
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy ( OX‐IRIS ) as Chemotherapy for Unresectable Pancreatic Cancer ( HGCSG 1403)
- (2021) Yasuyuki Kawamoto et al. ONCOLOGIST
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
- (2019) Takahiro Akahori et al. ONCOLOGIST
- A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
- (2018) Masato Ozaka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer
- (2018) Takuya Ishikawa et al. ONCOLOGY
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
- (2016) Stacey M Stein et al. BRITISH JOURNAL OF CANCER
- Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
- (2016) Hideki Ueno et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma
- (2015) Hiroaki Yanagimoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
- (2014) Takuji Okusaka et al. CANCER SCIENCE
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
- (2013) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
- (2010) Kei Muro et al. LANCET ONCOLOGY
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
- (2008) Jim Cassidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now